相关实验视频

Updated: May 11, 2025

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

铁化作为MDM2抑制在非分化脂肪肉瘤的治疗脆弱性

Chueh-Chuan Yen^1,2,3,4,5, Paul Chih-Hsueh Chen^3,4,6, San-Chi Chen^2,3,4,7

¹Department of Medical Research, Division of Clinical Research, Taipei Veterans General Hospital, Taipei 112201, Taiwan, R.O.C.

Oncology letters

|April 18, 2025

概括

作为细胞死亡途径的铁亡,在非分化脂肪瘤 (DDLPS) 中具有治疗上的脆弱性. 将MDM2抑制剂与诱导铁亡的药物结合起来,对DDLPS治疗有很大的前景.

科学领域:

在瘤学瘤学.
细胞死亡机制细胞死亡机制
癌症治疗方法癌症治疗方法

背景情况:

铁亡是一种受调节的死细胞死亡形式,由脂质过氧化驱动.
鼠标双分钟2同类 (MDM2) -瘤蛋白p53 (TP53) 途径在脂肪瘤发育中至关重要.
了解铁死在非分化脂肪瘤 (DDLPS) 中的作用,是新型治疗策略的关键.

研究的目的:

研究铁灭菌在DDLPS的治疗反应和耐药性中的作用.
探索结合MDM2抑制剂与DDLPS治疗中的ferroptosis诱导剂的潜力.

主要方法:

对WDLPS,DDLPS和脂肪组织的基因表达特征的分析.
在体外评估埃拉斯和RSL3对DDLPS细胞活力,脂质过氧化和亡的影响.
在DDLPS细胞系中结合素-3 (MDM2抑制剂) 与铁灭诱导剂的评估.

主要成果:

埃拉斯和RSL3诱导了脂质过氧化和亡,在DDLPS细胞中表现出细胞毒性作用.
努特林-3增强了脂质过氧化和细胞毒性,上调SLC3A2表达和囊的摄取.
与埃拉斯或RSL3结合的努特林-3显示出治疗潜力,影响信号通路.

结论:

铁化代表了DDLPS的显著治疗脆弱性,特别是在对MDM2抑制的反应中.
将MDM2抑制剂与诱导铁亡的药物结合起来,为DDLPS提供了一个有前途的治疗策略.
需要进一步研究mTOR在这些组合疗法的亲亡效应中的作用.

关键词:

在GPX4中使用GPX4.MDM2DM2 在线播放在RSL3中使用RSL3.这就是SLC3A2的原因.这就是TP53的特点.氨酸 (cystine) 是一种氨酸.埃拉斯廷没有离开.铁性化 (ferroptosis) 是一种脂肪肉瘤 (liposarcoma) 是一种这就是Nutlin-3的原因.xCTCTxCTxCTxCTxCTxCTxCTxCTxCTxCTxCT

更多相关视频

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Necrosis

Necrosis

Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...